Core Viewpoint - The announcement indicates that Weikang Pharmaceutical is collaborating with Yingkerui (Zhuhai Jinwan) Pharmaceutical Co., Ltd. to initiate a Phase III clinical trial for Huangjia Soft Liver Granules, aimed at evaluating its efficacy and safety in treating chronic hepatitis B-related liver fibrosis [1] Group 1 - Weikang Pharmaceutical and Yingkerui are jointly applying for a clinical trial [1] - The leading unit for the trial is Shanghai University of Traditional Chinese Medicine Affiliated Shuguang Hospital, with participation from 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing University Affiliated Three Gorges Hospital [1] - The trial is designed as a randomized, double-blind, multi-center, placebo-controlled study [1] Group 2 - The company will actively promote the Phase III clinical trial of Huangjia Soft Liver Granules in accordance with national requirements and expert recommendations following the project kickoff meeting [1]

Core Viewpoint - Weikang Pharmaceutical (300878.SZ) announced the initiation of a Phase III clinical trial to evaluate the efficacy and safety of Huangjia Soft Liver Granules in treating chronic hepatitis B virus-related liver fibrosis [1] Group 1: Clinical Trial Details - The clinical trial is a randomized, double-blind, multi-center, placebo-controlled study [1] - The trial is focused on patients with liver fibrosis due to chronic hepatitis B, specifically those with liver qi deficiency and blood stasis syndrome [1] - The project is led by Shuguang Hospital affiliated with Shanghai University of Traditional Chinese Medicine, along with 19 clinical trial centers including Anhui Medical University First Affiliated Hospital and Chongqing Medical University First Affiliated Hospital [1]

证券代码：300878 证券简称：维康药业 公告编号：2025-038 2、注册分类：中药 1.1 类 3、剂型：颗粒剂 关于黄甲软肝颗粒启动临床三期试验的公告 4、适应症：慢性乙型病毒性肝炎肝纤维化（肝郁脾虚兼瘀血阻络证） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 5、临床试验分期：Ⅲ期临床试验 2025 年 9 月 25 日，浙江维康药业股份有限公司(以下简称"公司")与盈科 瑞（珠海金湾）制药有限公司共同申办，牵头单位为上海中医药大学附属曙光医 院和参研的安徽医科大学第一附属医院、重庆大学附属三峡医院、重庆医科大学 附属第一医院等 19 家临床试验中心组织召开了关于开展"评价黄甲软肝颗粒治 疗慢性乙型病毒性肝炎肝纤维化（肝郁脾虚兼瘀血阻络证）的有效性和安全性的 随机、双盲、多中心、安慰剂对照的Ⅲ期临床试验"的项目启动会。现将主要相 关情况公告如下： 6、试验负责单位：上海中医药大学附属曙光医院 一、药品基本信息 浙江维康药业股份有限公司 1、药品名称：黄甲软肝颗粒 五、风险提示 本次Ⅲ期临床试验的启动将进一步推进黄甲软肝颗粒的上市进程。上述事项 属 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on September 25, with Enwei Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] Stock Performance - Notable gainers included: - Weikang Pharmaceutical, closing at 25.25 with a rise of 9.83% and a trading volume of 135,600 shares, totaling 329 million yuan [1] - Yisheng Pharmaceutical, closing at 7.98 with a rise of 1.53% and a trading volume of 80,000 shares, totaling 6.41 million yuan [1] - Major decliners included: - Enwei Pharmaceutical, closing at 32.25 with a drop of 3.09% and a trading volume of 8,950 shares, totaling 2.91 million yuan [2] - Zhendong Pharmaceutical, closing at 6.85 with a drop of 2.97% and a trading volume of 508,400 shares [2] Capital Flow - The Chinese medicine sector saw a net outflow of 462 million yuan from institutional investors, while retail investors contributed a net inflow of 315 million yuan [2] - The table of capital flow indicates that: - Wanbangde had a net inflow of 23.44 million yuan from institutional investors, but a net outflow of 29.29 million yuan from retail investors [3] - Jilin Aodong experienced a net inflow of 21.10 million yuan from institutional investors, with outflows from both retail and speculative investors [3]

证券之星消息，9月24日中药板块较上一交易日下跌0.28%，维康药业领跌。当日上证指数报收于 3853.64，上涨0.83%。深证成指报收于13356.14，上涨1.8%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.60 | 4.27% | 21.58万 | | 1.41亿 | | 600129 | 太极集团 | 21.75 | 3.97% | 16.50万 | | 3.54Z | | 603998 | 方盛制药 | 11.83 | 3.23% | 44.30万 | | 5.23亿 | | 300181 | 佐力药业 | 18.09 | 3.02% | 17.62万 | | 3.17亿 | | 000423 | 东阿阿胶 | 48.10 | 2.69% | 10.18万 | | 4.87亿 | | 600329 | 达仁堂 | 45.08 | 2.69% | 7.64万 | | 3.43亿 | | 300534 | ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [1][33]. Core Insights - The pharmaceutical and biotechnology sector experienced an overall decline of 2.07% from September 15 to September 19, ranking 23rd among 31 industries in the Shenwan index, underperforming the CSI 300 index by 1.63 percentage points. Year-to-date, the sector has risen by 24.17%, ranking 10th among the 31 industries and outperforming the CSI 300 index by 9.76 percentage points [3][12][16]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 31.18 times, which is at the historical median level, with a valuation premium of 136% compared to the CSI 300 index [3][19]. - The report highlights significant policy developments, including the completion of the review for the 2025 National Basic Medical Insurance Directory and the formal release of the 11th batch of national procurement documents, which includes 55 major varieties [4][27][28]. Market Performance - The pharmaceutical and biotechnology sector's performance for the week of September 15-19 showed a decline of 2.07%, with the top three declining sub-sectors being biological products (-3.47%), chemical pharmaceuticals (-2.43%), and traditional Chinese medicine II (-2.13%) [3][12]. - Year-to-date, the sector has increased by 24.17%, with the top three performing sub-sectors being medical services (46.19%), chemical pharmaceuticals (41.47%), and biological products (16.75%) [16][19]. Industry News - On September 20, the National Medical Insurance Administration completed the review of the 2025 National Basic Medical Insurance Directory and the commercial insurance innovative drug directory, moving into the core negotiation and pricing phase [4][27]. - The 11th batch of national procurement was officially released on September 20, optimizing the requirements for bidding companies and the rules for procurement, which is expected to be a significant turning point for the industry [4][28]. - The Shanghai Municipal Government issued a plan to promote the development of the high-end medical device industry, aiming to enhance innovation and international competitiveness by 2027 [4][29]. Investment Recommendations - The report suggests focusing on the progress of the medical insurance directory negotiations and the implications of the national procurement policies. It recommends investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [5][30]. - Recommended stocks include Teva Biopharmaceuticals, Rongchang Biopharmaceuticals, Betta Pharmaceuticals, Kaili Medical, and Huaxia Eye Hospital, with additional stocks to watch including Kelun Pharmaceutical, Qianhong Pharmaceutical, Yifeng Pharmacy, Baipusais, and Lingrui Pharmaceutical [5][30].

Market Overview - The Chinese medicine sector experienced a decline of 0.57% on September 22, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3828.58, up 0.22%, while the Shenzhen Component Index closed at 13157.97, up 0.67% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Tianmu Pharmaceutical: closed at 18.31, up 2.29% with a trading volume of 35,700 shares [1] - Fangsheng Pharmaceutical: closed at 11.02, up 2.23% with a trading volume of 186,100 shares [1] - Jiuzi Tang: closed at 10.34, up 1.77% with a trading volume of 169,900 shares [1] - Conversely, Zhongsheng Pharmaceutical saw a significant decline, closing at 18.52, down 6.28% with a trading volume of 974,000 shares [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 429 million yuan from institutional investors, while retail investors saw a net inflow of 392 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remained active [2] Individual Stock Capital Flow - Key stocks with notable capital flow include: - Zhendong Pharmaceutical: net inflow of 31.47 million yuan from institutional investors [3] - Daren Tang: net inflow of 27.08 million yuan from institutional investors [3] - Jiuzi Tang: net inflow of 18.17 million yuan from institutional investors [3] - Stocks like Daren Tang and Jiuzi Tang experienced negative net inflows from retail investors, indicating a divergence in investor sentiment [3]

Core Insights - The latest financing balance of the ChiNext market is 503.632 billion yuan, a decrease of 2.051 billion yuan compared to the previous period, with 37 stocks experiencing a financing balance increase of over 10% [1] - On September 19, the ChiNext index fell by 0.16%, with a total margin balance of 505.245 billion yuan, down by 2.063 billion yuan from the previous trading day [1] - Among the stocks with increased financing balances, the largest increase was seen in Weikang Pharmaceutical, which had a financing balance of 46.5396 million yuan, up by 35.67% [1][3] Financing Balance Increase - A total of 358 stocks in the ChiNext market saw an increase in financing balance, with 37 stocks increasing by more than 10% [1] - The stocks with significant financing balance increases include: - Weikang Pharmaceutical: 46.5396 million yuan, +35.67%, closing price 23.80 yuan, +6.06% [3] - Kailong High-Tech: 90.1017 million yuan, +34.63%, closing price 19.00 yuan, -7.27% [3] - Kalait: 176.0133 million yuan, +30.05%, closing price 71.84 yuan, +14.29% [3] - The average increase for stocks with over 10% financing balance growth was 2.11%, with notable performers including Kalait, Tongyu New Materials, and Suzhou Tianmai, which saw increases of 14.29%, 12.14%, and 11.55% respectively [1][3] Financing Balance Decrease - A total of 586 stocks experienced a decrease in financing balance, with 10 stocks seeing a decline of over 10% [4] - The stocks with the largest decreases in financing balance include: - Junting Hotel: 16.921 million yuan, -17.52%, closing price 26.47 yuan, +3.16% [4] - Wavelength Optoelectronics: 36.291 million yuan, -17.37%, closing price 108.30 yuan, +14.60% [4] - Fushite: 5.4887 million yuan, -16.62%, closing price 32.72 yuan, -3.71% [4] Fund Flow - On September 19, among the stocks with increased financing balances, 25 stocks saw net inflows of main funds, with the highest inflows in Kunlun Wanwei, Capital Online, and Sanhuan Group, amounting to 573 million yuan, 182 million yuan, and 123 million yuan respectively [2] - Conversely, 12 stocks experienced net outflows, with the largest outflows in Lihexing, Suao Sensor, and Sudawige, totaling 178 million yuan, 75.5 million yuan, and 46.1427 million yuan respectively [2]

Core Insights - The latest financing balance of the ChiNext market is 503.63 billion yuan, with a week-on-week decrease of 2.05 billion yuan, while 37 stocks saw a financing balance increase of over 10% [1] - On September 19, the ChiNext index fell by 0.16%, with a total margin balance of 505.25 billion yuan, down 2.06 billion yuan from the previous trading day [1] - The stock with the largest increase in financing balance is Weikang Pharmaceutical, which saw a 35.67% increase, while the stock with the largest decrease is Junting Hotel, with a 17.52% decrease [4] Financing Balance Overview - The total financing balance of ChiNext stocks is 503.63 billion yuan, with a decrease of 2.05 billion yuan from the previous day [1] - The margin balance includes a financing balance of 503.63 billion yuan and a securities lending balance of 1.61 billion yuan, with the latter decreasing by 11.86 million yuan [1] - A total of 358 stocks experienced an increase in financing balance, with 37 stocks increasing by over 10% [1] Stocks with Increased Financing Balance - Weikang Pharmaceutical (300878) had a financing balance of 46.54 million yuan, increasing by 35.67% and closing at 23.80 yuan, with a daily increase of 6.06% [3] - Other notable increases include Kailong High-Tech (300912) with a 34.63% increase and Kaleite (301391) with a 30.05% increase [3] - The average increase for stocks with over 10% financing balance growth was 2.11%, with 24 stocks rising, including notable performers like Kaleite and Tongyu New Materials [1][3] Stocks with Decreased Financing Balance - A total of 586 stocks saw a decrease in financing balance, with 10 stocks decreasing by over 10% [4] - Junting Hotel (301073) had the largest decrease at 17.52%, with a financing balance of 16.92 million yuan [4] - Other significant decreases include Boshang Optoelectronics (301421) with a 17.37% decrease and Fushite (301446) with a 16.62% decrease [4] Capital Flow Insights - On September 19, 25 stocks saw net inflows of main funds, with Kunlun Wanwei receiving the highest net inflow of 573 million yuan [2] - Conversely, 12 stocks experienced net outflows, with Lihexing seeing the largest outflow of 178 million yuan [2]

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - The adjustment of medical insurance and commercial insurance directories will enter the price negotiation stage, and attention should be paid to the progress of subsequent stages [7] - The market performance of the traditional Chinese medicine sector has shown a decline, with the TCM index dropping by 2.13% last week [3][12] - The demand for traditional Chinese medicinal materials remains relatively stable, while supply has increased due to the new harvest, leading to a slight decrease in price indices [6] Market Performance - The traditional Chinese medicine sector reported a decline of 2.13%, while the overall pharmaceutical sector fell by 2.07% [3][12] - The performance of individual companies varied, with leading companies including Weikang Pharmaceutical and Wanbangde, while companies like Jiuzhitang and Xintian Pharmaceutical lagged behind [4] Valuation - The TCM sector's PE (ttm) is 27.92X, down by 0.6X week-on-week, with a one-year maximum of 30.26X and a minimum of 22.85X [5] - The PB (lf) stands at 2.36X, also down by 0.06X week-on-week, with a one-year maximum of 2.65X and a minimum of 2.02X [5] Investment Suggestions - The report suggests focusing on three main investment lines: 1. Price governance, emphasizing the importance of price reduction and market share for competitive products [8][9] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population [10] 3. State-owned enterprise reform, which presents investment opportunities through performance enhancement [10] - Recommended stocks include Zhaoli Pharmaceutical, Pizaihuang, and Shouxiangu [10]